MedTrace Logo

Metabolomic Study for Localized Prostate Cancer

NCT01968538 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2023-02-28

No results posted yet for this study

Summary

Prostate cancer is a common disease in men treated using surgery, radiation therapy and/or hormonal therapy. Clinical prognosis relates to stage and grade of disease. Recent advances in omic analysis may offer additional information to the physician about prognosis and radiation response. We propose to establish a protocol to incorporate omic analysis into the evaluation and treatment of patients with prostate cancer.

Conditions

Interventions

RADIATION

Radiation Therapy

Sponsors & Collaborators

  • Georgetown University

    lead OTHER

Principal Investigators

  • Sean P Collins, MD, PhD · Georgetown University Hospital

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01968538 on ClinicalTrials.gov